Deep brain stimulation can be effective for severe depression

By

Researchers who monitored people with deep brain stimulation implants for 8 years suggest that the treatment can benefit those with severe depression.

Regulators in the United States have already approved deep brain stimulation for the treatment of Parkinson’s disease, epilepsy, essential tremor, and obsessive-compulsive disorder.

The treatment involves implanting wires into the brain and a stimulator in the chest or abdomen.

The stimulator sends small electrical pulses to the wires along a connection lead under the skin. Doctors sometimes refer to the stimulator as a pacemaker. If you want to read more about this news, click here.

Posted in News, Science.
Share

Deja una respuesta

Tu dirección de correo electrónico no será publicada.

Related Posts

  •
    10 octubre, 2019

    AI-enhanced ECGs may soon assess overall health

    Scientists have trained an artificial intelligence tool to predict sex and estimate age from electrocardiogram readouts. They suggest that, with further development, the tool could soon be helping doctors to assess the overall health of their patients. An electrocardiogram, also known as an ECG or EKG, is a painless, simple test that records the electrical …

  •
    30 diciembre, 2019

    Researchers produce first laser ultrasound images of humans.

    «Engineers have come up with an alternative to conventional ultrasound that doesn’t require contact with the body to see inside a patient. The new laser ultrasound technique leverages an eye- and skin-safe laser system to remotely image the inside of a person.»   Read more

  •
    10 octubre, 2019

    Study: Abbott, Edwards may have mislabeled hundreds of patient deaths

    Abbott (NYSE:ABT) and Edwards Lifesciences (NYSE:EW) may have mislabeled patient deaths as injuries or device malfunctions in hundreds of FDA adverse event reports involving their transcatheter aortic or mitral valve replacement devices, according to a new study. The study by JAMA Internal Medicine editor Dr. Rita Redberg, former FDA unique device identification (UDI) external program manager Madris Tomes and others examined a total …

  •
    10 octubre, 2019

    Medtronic announces Infuse spine trial

    Medtronic (NYSE:MDT) said today that it won FDA approval for a clinical trial of its Infuse bone graft in transforaminal lumbar interbody fusion spine procedures. The Minneapolis-based company started recruiting for the prospective, randomized pivotal trial, which is slated to enroll up to 1,000 patients. The TLIF trial would be the second clinical trial for Infuse, …